Vaccine safety alert: Jab rolled out to millions 'could cause neurological illness', health chiefs warn
US health chiefs issued a warning about RSV jabs, which were only launched in Britain last year.In the UK, the condition is ...
GB News on MSN22h
New jab offered to millions of pensioners and pregnant women 'could cause neurological illness' as health chiefs issue vaccine safety alert
US health officials have issued a warning linking RSV vaccines to an increased risk of a serious neurological condition. The ...
dermatologyadvisor3d
FDA Alert: Pulmonology Drug Approvals, Recalls, and Device Updates
FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.
Jab given to Brits 'could cause serious neurological condition', health experts warn
A jab given to patients to battle RSV through the NHS could potentially cause a disabling condition known as Guillain-Barré ...
Yahoo Finance3d
GSK plc (GSK)
“Faisal has a proven track record in integrating cutting-edge science with practical, evidence-base PHILADELPHIA, October 24, 2024--New data for AREXVY, GSK’s RSV vaccine, show potential to ...
pharmaphorum1d
Alarm bell rings for GSK as US policy dents RSV jab sales
Sales of GSK's respiratory syncytial virus (RSV) vaccine Arexvy slumped 72% in the third quarter of this year, as narrower recommendations on its use in the US started to have an effect.
infectiousdiseaseadvisor.com21h
Prefilled Syringe Presentation of Shingrix Under FDA Review
The FDA will review a new prefilled syringe presentation of Shingrix (zoster vaccine recombinant, adjuvanted).
pharmaphorum5d
GSK targets younger age group with RSV jab Arexvy
GSK has reported new clinical data pointing to a benefit with its respiratory syncytial virus (RSV) vaccine Arexvy when used to treat a younger age group than the over-60s for whom it is approved.